Receptors and signaling pathways
How a cell receives a chemical signal: the receptor families that bind it, the terms pharmacologists use to describe binding and response, nine pathways that carry the signal inward, the liver sensors that respond to foreign compounds, and why a concentration that works in a dish may never occur in a person.
Alexander SPH, et al. Br J Pharmacol 2025;182(Suppl 1):S24–S151 and S259–S306; Lemmon MA, Schlessinger J. Cell 2010;141:1117–1134; Frigo DE, et al. Essays Biochem 2021;65:847–856; Moore LB, et al. Proc Natl Acad Sci USA 2000;97:7500–7502.
Status. Education, not medical advice. This page explains textbook physiology and pharmacology; it gives no dosing advice and makes no claim that any supplement treats or prevents a disease. The two computed figures are educational calculations, not measurements. EUTECNIQ is in formation and has no laboratory or studies running.
Related: ADME, PK and PBPK · Bioactive compounds · Bioavailability design
Five receptor types turn a bound chemical signal into a response
A receptor is a protein that binds a signaling molecule and changes shape, so that binding becomes a response. Four types sit in the cell membrane and read signals from outside; nuclear receptors sit inside the cell and bind DNA.
Speed and reach differ: an ion channel opens on a millisecond time scale, while a nuclear receptor acts by changing which genes are transcribed.
Explanation, details and sources
| Receptor type | Structure | What binding does | Human members, as the source states |
|---|---|---|---|
| G protein-coupled receptors (GPCRs) | One chain with an extracellular N-terminus, seven transmembrane helices (TM1–TM7) joined by three extracellular and three intracellular loops, and an intracellular C-terminus | The receptor acts as a guanine nucleotide exchange factor: Gα releases GDP, binds GTP and separates from Gβγ; both parts then regulate effectors | About 800, about half sensory; about 350 non-sensory receptors are the targets of most drugs in clinical use |
| Ligand-gated ion channels | nACh, 5-HT3, GABAA and glycine receptors (and the zinc-activated channel) are pentamers, the Cys-loop receptors; ionotropic glutamate receptors are tetramers; P2X receptors are trimers | A transmitter binds the orthosteric site and the pore opens; ions flow down their electrochemical gradient, giving fast synaptic transmission on a millisecond time scale | Grouped by family in the Concise Guide; no single total given |
| Receptor tyrosine kinases (RTKs) | Extracellular ligand-binding domain, one transmembrane helix, intracellular tyrosine kinase domain | The ligand induces dimerization (insulin and IGF1 receptors are already disulfide-linked dimers); the kinases phosphorylate each other in trans, creating docking sites for PLCγ, MAP kinase and PI3K pathways | 58 RTKs in 20 subfamilies |
| Cytokine receptors (with JAKs) | Type I receptors carry a WSXWS motif in the cytokine receptor homology domain; type II receptors lack it | Binding recruits intracellular partners; for most cytokine receptors these are Janus kinases (JAKs), whose tyrosine kinase activity phosphorylates the receptor and recruits STATs | 4 JAKs (JAK1, JAK2, JAK3, TYK2) and 7 STATs; more than 50 cytokines and growth factors signal this way |
| Nuclear receptors | Domains A/B (AF-1), C (DNA-binding, two zinc fingers), D (hinge with nuclear localization signal), E (ligand-binding, AF-2) and F | Most ligands are small lipophilic compounds that diffuse across the plasma membrane; the receptor binds hormone response elements in DNA as a homodimer, heterodimer or monomer and recruits coregulators | 48 |
Alexander SPH, et al. The Concise Guide to PHARMACOLOGY 2025/26: G protein-coupled receptors. Br J Pharmacol 2025;182(Suppl 1):S24–S151; Syrovatkina V, et al. J Mol Biol 2016;428:3850–3868; Alexander SPH, et al. Concise Guide 2023/24: Ion channels. Br J Pharmacol 2023;180(Suppl 2):S145–S222; Lemmon MA, Schlessinger J. Cell 2010;141:1117–1134; Alexander SPH, et al. Concise Guide 2025/26: Catalytic receptors. Br J Pharmacol 2025;182(Suppl 1):S259–S306; Hu X, et al. Signal Transduct Target Ther 2021;6:402; Frigo DE, Bondesson M, Williams C. Essays Biochem 2021;65:847–856; Alexander SPH, et al. Concise Guide 2025/26: Nuclear hormone receptors. Br J Pharmacol 2025;182(Suppl 1):S242–S258.
Gα proteins form four families: Gαs (stimulates adenylyl cyclase), Gαi (inhibits some adenylyl cyclase isoforms), Gαq (activates phospholipase Cβ) and Gα12. Humans have 5 Gβ and 12 Gγ genes (Syrovatkina et al. 2016). The catalytic-receptor superfamily also includes guanylyl cyclase receptors, receptor serine/threonine kinases such as the TGF-β and BMP receptors, receptor tyrosine phosphatases and integrins (Concise Guide 2025/26).
Show data: human GPCRs by class
| Class | Known ligands | Orphans | Sensory | Total |
|---|---|---|---|---|
| Class A (rhodopsin) | 197 | 87 | 435 | 719 |
| Class B (secretin) | 15 | — | — | 15 |
| Class C (glutamate) | 12 | 8 | 3 | 23 |
| Adhesion | 0 | 33 | — | 33 |
| Frizzled | 11 | 0 | — | 11 |
The guide's text gives the rounded totals: about 800 GPCRs, about 400 olfactory, 33 taste, 10 light and 5 pheromone receptors, and about 350 non-sensory receptors. Sensory class A total (435) summed on this page from the table.
Affinity, efficacy and potency are different properties
Affinity says how tightly a compound binds; efficacy says what the bound receptor then does; potency says how much compound is needed for a given effect. A compound can bind tightly and do nothing, which is how a competitive antagonist works. The equation that links concentration to effect is the Hill equation, explained on the ADME and PK page.
| Term | Definition | Source |
|---|---|---|
| Affinity | The ability of a drug to bind a receptor; numerically 1/KD, where KD, the equilibrium dissociation constant, is the concentration that occupies 50% of the receptors | Berg and Clarke 2018 |
| Intrinsic efficacy | The effect a drug has on receptor activity once bound; a constant for each drug–receptor pair that cannot be measured directly, so it is expressed relative to a reference drug | Berg and Clarke 2018 |
| Potency | The amount of drug needed to produce an effect of a given size, usually given as EC50 or ED50; affinity is one of the factors that set it | Salahudeen and Nishtala 2017 |
| Agonist | Activates the receptor to produce a response; some agonists reach the maximal response without occupying all receptors | Salahudeen and Nishtala 2017 |
| Partial agonist | Binds and activates but cannot produce the full response; at high concentration it can reduce the effect of a full agonist to its own maximum | Salahudeen and Nishtala 2017 |
| Antagonist | Binds without producing a response and blocks the agonist. A competitive antagonist binds reversibly at the agonist's site and shifts the concentration–response curve to the right without lowering the maximum | Salahudeen and Nishtala 2017; Wyllie and Chen 2007 |
| Inverse agonist | Has negative intrinsic efficacy: it lowers the activity a receptor shows without any ligand (constitutive activity). Many clinically used drugs first classed as antagonists show inverse agonist properties in suitable test systems | Berg and Clarke 2018 |
| Allosteric modulator | Binds a site topographically distinct from the orthosteric (agonist) site and changes the receptor's affinity for, or response to, the orthosteric ligand. A cooperativity factor α > 1 is positive (potentiation, PAM), 0 < α < 1 negative (NAM), α = 1 neutral | Conn, Christopoulos and Lindsley 2009 |
Berg KA, Clarke WP. Int J Neuropsychopharmacol 2018;21:962–977; Salahudeen MS, Nishtala PS. Saudi Pharm J 2017;25:165–175; Wyllie DJA, Chen PE. Br J Pharmacol 2007;150:541–551; Conn PJ, Christopoulos A, Lindsley CW. Nat Rev Drug Discov 2009;8:41–54.
For a competitive antagonist B, Wyllie and Chen write the Schild equation in normalized concentrations, r = 1 + cB, where cB = [B]/KB and the dose ratio r is the factor by which agonist concentration must rise to restore the response seen without antagonist. The equation contains no term for the agonist or its efficacy.
Show data: dose ratios in the calculation
| [B]/KB | Dose ratio r = 1 + [B]/KB | Apparent EC50 (multiples of the control EC50) | log10(r − 1) |
|---|---|---|---|
| 0 | 1 | 1 | — |
| 1 | 2 | 2 | 0 |
| 10 | 11 | 11 | 1 |
| 100 | 101 | 101 | 2 |
Wyllie and Chen's tests for competitive antagonism are parallel rightward shifts with no fall in the maximum response. A log–log plot of r − 1 against antagonist concentration then gives a straight line of slope 1, and only then does its intercept estimate KB. pA2, the negative log of the antagonist concentration that gives r = 2, equals −log10 KB only when the slope is 1.
Nine pathways carry a receptor signal to its target
Behind each receptor is a chain of enzymes, small messenger molecules and transcription factors. Arrows below mean “activates” and flat-ended lines mean “inhibits”. Each drawing shows the core steps the cited review describes, not every branch.
Text version: cAMP/PKA, Gq/PLC/PKC and NO/cGMP
| Pathway | Steps | Source |
|---|---|---|
| cAMP / PKA | A GPCR activates Gαs, which stimulates adenylyl cyclase to make cAMP from ATP; Gαi inhibits some cyclase isoforms. cAMP activates PKA, cyclic nucleotide-gated channels and EPAC. In cells PKA is mostly an inactive tetramer; cAMP binding to its regulatory subunits frees the catalytic subunits, which reach the nucleus and phosphorylate CREB at Ser133. Transcription peaks 30 minutes to 1 hour after cAMP rises, at genes with cAMP response elements (palindrome TGACGTCA or half-sites) | Syrovatkina 2016; Taylor 2013; Altarejos and Montminy 2011 |
| Gq / PLCβ / IP3 / DAG / Ca2+ / PKC | Gαq activates PLCβ1–4, which cleaves PIP2 into soluble IP3 and membrane-bound DAG. IP3 opens the IP3 receptor Ca2+ channel of the endoplasmic reticulum; DAG activates PKC. Conventional PKCs need DAG (C1 domain) and Ca2+ (C2 domain); novel PKCs bind DAG but are not Ca2+-sensitive; atypical PKCs bind neither and are activated by protein scaffolds | Syrovatkina 2016; Newton 2018 |
| NO / cGMP | Three NO synthases (nNOS/NOS1, iNOS/NOS2, eNOS/NOS3) make NO and L-citrulline from L-arginine and O2 with electrons from NADPH; nNOS and eNOS depend on Ca2+-calmodulin. NO stimulates soluble guanylyl cyclase, cGMP rises and vascular smooth muscle relaxes. cGMP binds PKG and raises its kinase activity 3- to 10-fold; phosphodiesterases such as PDE5 hydrolyze cGMP | Cyr 2020; Francis 2010 |
Text version: MAPK/ERK, PI3K/AKT/mTOR and JAK/STAT
| Pathway | Steps | Source |
|---|---|---|
| MAPK / ERK | The adaptor Grb2 binds the activated receptor and recruits SOS to the membrane, where SOS exchanges GDP for GTP on Ras. Ras-GTP activates Raf; Raf activates MEK1/2, dual-specificity kinases that phosphorylate ERK at two regulatory sites, Thr202/185 and Tyr204/187. Active ERK enters the nucleus and regulates transcription factors. ERK1 is 44 kDa, ERK2 42 kDa. ERK1/2 is one of four MAPK cascades, with JNK, p38 and ERK5 | Guo 2020 |
| PI3K / AKT / mTOR | RTKs or GPCRs recruit class I PI3K, which makes PIP3; the PIP3 phosphatase PTEN terminates the signal. AKT is fully active when PDK1 phosphorylates Thr308 and mTORC2 phosphorylates Ser473. AKT phosphorylates and inhibits TSC2. The TSC complex (TSC1, TSC2, TBC1D7) is a GAP for Rheb, and Rheb-GTP activates mTORC1, which phosphorylates S6K1 (Thr389) and 4EBP to drive protein synthesis | Manning and Toker 2017; Saxton and Sabatini 2017 |
| JAK / STAT | Ligand binding brings receptor chains together (some, such as gp130 and the GH receptor, are pre-formed dimers). The JAKs phosphorylate each other and then the receptor, creating docking sites for STATs. JAK phosphorylates the docked STAT, which leaves the receptor, dimerizes through SH2–phosphotyrosine contacts and moves to target-gene promoters. PIAS proteins, SOCS/CIS proteins and protein tyrosine phosphatases switch the pathway off | Hu 2021 |
Text version: AMPK, NF-κB and Nrf2/Keap1/ARE
| Pathway | Steps | Source |
|---|---|---|
| AMPK | AMPK is an αβγ heterotrimer. Its activity rises more than 100-fold when Thr172 is phosphorylated, mainly by the LKB1 complex or by CaMKKβ after a Ca2+ rise. AMP and ADP binding to the γ subunit promotes that phosphorylation and slows its removal; AMP also activates allosterically, up to about 10-fold. Active AMPK increases ATP-producing catabolism and switches off biosynthesis. It inhibits mTORC1 by phosphorylating and activating TSC2 and by phosphorylating Raptor | Hardie 2012; Saxton and Sabatini 2017 |
| NF-κB (canonical) | The family has five members: p50, p52, RelA (p65), RelB and c-Rel. IκB proteins hold them in the cytoplasm. Cytokine receptors, pattern-recognition receptors and TNF receptors activate the IKK complex (IKKα, IKKβ, NEMO); pattern-recognition receptor pathways converge on TAK1, which activates IKK. IKK phosphorylates IκBα at two N-terminal serines, and IκBα is ubiquitylated and degraded in the proteasome. p50/RelA and p50/c-Rel dimers then enter the nucleus. The noncanonical pathway instead processes p100 to p52 through NIK and IKKα | Liu 2017 |
| Nrf2 / Keap1 / ARE | Without stress, two Keap1 molecules bind Nrf2 at its ETGE and DLG motifs; Keap1 is the adaptor for the Cul3 E3 ubiquitin ligase, so Nrf2 is continuously ubiquitylated and degraded, with a half-life of about 10–30 min. Oxidation of reactive Keap1 cysteines inactivates Keap1; Nrf2 accumulates, enters the nucleus, pairs with a small Maf protein (MafF, MafG or MafK) and binds the antioxidant response element (ARE). Targets include NQO1, glutathione S-transferases, the GCLC and GCLM subunits of glutamate-cysteine ligase, HMOX1 and G6PD | Tonelli 2018 |
Pathways cross-connect: AKT also phosphorylates c-Raf and inhibits it (Manning and Toker 2017), and the AhR, described in the next section, can induce the gene for Nrf2 (Tonelli et al. 2018).
The liver senses foreign compounds through PXR, CAR and AhR
Three receptors detect drugs, food chemicals and pollutants and respond by making more of the enzymes and transporters that clear them. This is induction. Its effect on another drug's exposure, and the FDA potency categories, are on the ADME page; the enzymes themselves are introduced in its first-pass section.
PXR is activated only by ligand binding and has a large, flexible binding pocket, so it responds to many unrelated structures (Tolson and Wang 2010).
Explanation, details and sources
PXR and CAR are NR1I nuclear receptors that form heterodimers with RXR. Neither has an established endogenous physiological agonist, although high concentrations of bile acids and bile pigments activate both (Concise Guide 2025/26). They regulate a largely overlapping set of genes: CYP3A4, CYP2B6, CYP2Cs and CYP2A6; UGT1A1, UGT1A6 and UGT1A9; GSTs and SULTs; and the transporters MDR1 (P-gp), MRPs and OATPs. Most known CAR activators act indirectly, without binding the receptor, and in primary hepatocytes CAR waits in the cytoplasm until activated (Tolson and Wang 2010).
The AhR is a cytoplasmic protein held in a complex with two HSP90 molecules, p23 and XAP2. A ligand that diffuses into the cell binds its PAS B domain; the receptor moves to the nucleus, pairs with ARNT and binds xenobiotic response elements. One target is its own repressor, AhRR. Ligands include dioxins, PCBs and polycyclic aromatic hydrocarbons; dietary flavonoids such as quercetin and resveratrol; indole-3-carbinol from cruciferous vegetables; and tryptophan metabolites such as FICZ. Quercetin and resveratrol are reported to act as both agonists and antagonists (Larigot et al. 2018, review).
| ICH M12 element | What the guideline says |
|---|---|
| Receptors to consider | Induction via PXR, CAR, AhR and, if relevant, other pathways should be evaluated |
| Test system | Human hepatocytes from at least 3 individual donors; induction measured at the mRNA level |
| Marker enzymes | Always CYP3A4 and CYP2B6 (PXR/CAR) and CYP1A2 (AhR); CYP2C8, CYP2C9 and CYP2C19 are induced via PXR but are generally less inducible than CYP3A4 |
| Basic mRNA fold-change criterion | Induction cannot be excluded if, in at least one donor, CYP mRNA rises in a concentration-dependent way and reaches ≥ 2-fold at concentrations below 50 × Cmax,u (unbound peak plasma concentration) |
| Assay sensitivity | Positive controls normally raise CYP1A2, CYP2B6 and CYP3A4 mRNA at least 6-fold |
| Clinical categories | A strong inducer lowers the AUC of a sensitive index substrate by ≥ 80%, a moderate one by ≥ 50 to < 80%, a weak one by ≥ 20 to < 50% |
ICH M12 Guideline, Drug Interaction Studies, final version adopted May 21, 2024: sections 2.1.4, 2.1.4.1 and 7.3.4, and the inducer classification in section 5.3.2. The guideline addresses investigational drugs.
St John's wort shows the mechanism in people. Hyperforin binds PXR with a Ki of 27 nM, and hypericum extract or hyperforin markedly induced CYP3A4 in primary human hepatocytes (Moore et al. 2000, in vitro). Studies in healthy volunteers then measured the enzymes directly.
Show data: St John's wort and enzyme measures in people
| Study | Participants and product | Measure | Result |
|---|---|---|---|
| Dürr et al. 2000 | 8 healthy men; extract for 14 days | Duodenal P-gp/MDR1 and CYP3A4 protein; erythromycin breath test; digoxin | P-gp 1.4-fold, CYP3A4 1.5-fold; hepatic CYP3A4 activity 1.4-fold; digoxin exposure −18% |
| Markowitz et al. 2003 | 12 healthy adults (6 men, 6 women); 300 mg tablet three times a day for 14 days | Alprazolam (CYP3A4); dextromethorphan/dextrorphan in urine (CYP2D6) | Alprazolam AUC halved, clearance doubled, half-life 12.4 (SD 3.9) → 6.0 (2.4) h; CYP2D6 ratio 0.006 → 0.014, P =.26 |
| Wenk et al. 2004 | 8 men, 8 women; 300 mg extract three times a day for 14 days | Urinary 6β-hydroxycortisol/cortisol (CYP3A4); caffeine metabolite ratios (CYP1A2) | CYP3A4 1.5 (95% CI 1.3–1.9) men, 1.9 (1.1–3.0) women; CYP1A2 1.2 (1.1–1.4) in women only; CYP2D6, NAT2 and xanthine oxidase not affected |
| Lei et al. 2010 | 18 healthy Chinese men; 325 mg three times a day for 14 days | Bupropion, a CYP2B6 substrate | Oral clearance 108.3 → 130.0 L/h; AUC0–∞ 1.4 → 1.2 µg·h/mL; half-life unchanged |
Values from the published abstracts. Wenk et al. also report dextromethorphan ratios (0.9 in men, 1.9 in women) that their abstract's conclusion does not treat as a CYP2D6 effect; they are not plotted. The midazolam studies of St John's wort and goldenseal, with FDA potency bands, are on the ADME page. Ingredient entries: St. John's wort, Goldenseal.
Diet moves these enzymes too. In a randomized crossover feeding study, 36 non-smoking adults had higher CYP1A2 activity on a brassica-vegetable diet and lower activity on an apiaceous-vegetable diet, measured by caffeine metabolite ratios (Lampe et al. 2000). The study did not test which receptor was responsible.
Lampe JW, et al. Carcinogenesis 2000;21:1157–1162.
For curcumin and quercetin, cell-study concentrations sit above what human blood reaches
A pathway result from cultured cells shows what a compound can do at the concentration tested, in the form tested. In people, polyphenols such as curcumin and quercetin circulate mostly as glucuronide and sulfate conjugates, at concentrations below those at which the cell studies in the figure report effects.
Show data: concentrations in the figure
| Compound and setting | Value as published | µmol/L | Source |
|---|---|---|---|
| Curcumin, TNF-α and IL-1β effects in RAW 264.7 mouse macrophages | 100 µM | 100 | Abdel-Tawab 2021 |
| Curcumin, cytotoxicity IC50, human kidney cells and murine macrophage line | 15.2 and 31 µM | 15.2–31 | Nelson 2017 |
| Curcumin, critical aggregation concentration in assays | 10–20 µM, “common compound testing concentrations” | 10–20 | Nelson 2017 |
| Curcumin, NF-κB inhibition IC50, TNF-α-stimulated A549 cells | 10–20 µM | 10–20 | Abdel-Tawab 2021 |
| Free curcumin in serum, single doses of 10 or 12 g (12 healthy adults) | Detected in 1 subject; detection limit 50 ng/mL. Glucuronide and sulfate conjugates found in all | below 0.136 in 11 of 12 | Vareed 2008 |
| Curcumin in serum, single doses of 0.5–8 g (healthy adults) | Not detected; detection limit 0.031 µg/mL | below 0.084 | Lao 2006 |
| Quercetin, cytokine secretion blocked in LPS-stimulated human whole blood | 25 µM | 25 | Abdel-Tawab 2021 |
| Quercetin, NF-κB signaling IC50 | 4–11 µM | 4–11 | Abdel-Tawab 2021 |
| Quercetin, Raf/MEK1/ERK IC50 | 1–10 µM | 1–10 | Abdel-Tawab 2021 |
| Quercetin, JAK3 IC50 | 2 µM | 2 | Abdel-Tawab 2021 |
| Plasma quercetin, median Cmax after 150 mg quercetin (subgroup of 15) | 431 nmol/L, at 360 min | 0.431 | Egert 2008 |
| Quercetin conjugates in plasma after lightly fried onions with 275 µmol flavonols | Sub-micromolar Cmax for each of four conjugates, at 0.6–0.8 h | below 1 each | Mullen 2006 |
| Peak plasma polyphenols after a polyphenol-rich meal | 0.1–10 µmol/L | 0.1–10 | Kroon 2004 |
- Activity in a cell assay at 10 µmol/L≠the same activity in a person whose blood holds 0.4 µmol/L
- The aglycone tested in the dish≠the glucuronide and sulfate conjugates that circulate
- Activating a pathway in cells≠a demonstrated health effect in people
Explanation, details and sources
Kroon et al. (2004) named two flaws in typical polyphenol cell studies. Cells are treated with aglycones or extracts, although first-pass metabolism means plasma and tissues meet mostly conjugates (green tea catechins are the exception). And concentrations should be of the same order as the peak plasma concentrations reached after a polyphenol-rich meal, 0.1–10 µmol/L. Across 97 human studies, total plasma metabolites ranged from 0 to 4 µmol/L after 50 mg aglycone equivalents (Manach et al. 2005).
Measured forms matter. After onions, Mullen et al. (2006) quantified five flavonol conjugates in plasma and noted that hydrolysis, used in many earlier studies, would have reported only quercetin and isorhamnetin. Vareed et al. (2008) found free curcumin in 1 of 12 subjects, while glucuronide and sulfate conjugates appeared in all; a one-compartment pharmacokinetic model fitted to their serum data estimated a Cmax of 2.30 ± 0.26 µg/mL (mean ± SE) after 10 g for the curcumin glucuronide and sulfate conjugates, not free curcumin. For curcumin bioavailability formulations and what their studies measured, see the ADME page.
Assay artifacts add a second gap. Nelson et al. (2017) describe curcumin as unstable, chemically reactive and aggregating, note reports that label it a pan-assay interference compound (PAINS), and give a critical aggregation concentration of 10–20 µM that matches common testing concentrations; detergent raised its apparent IC50 against three enzymes. Their review concludes that no form of curcumin or its close analogues has the properties of a good drug candidate. For AMPK, Hardie et al. (2012) list resveratrol, EGCG, capsaicin, curcumin, garlic and berberine among plant products that switch AMPK on in cells; most act in intact cells but not in cell-free assays, and resveratrol, like metformin, does so indirectly, usually by inhibiting mitochondrial ATP synthesis.
Kroon PA, et al. Am J Clin Nutr 2004;80:15–21; Manach C, et al. Am J Clin Nutr 2005;81(1 Suppl):230S–242S; Mullen W, Edwards CA, Crozier A. Br J Nutr 2006;96:107–116; Vareed SK, et al. 2008; Nelson KM, et al. 2017; Hardie DG, et al. 2012. Ingredient entries: Turmeric, Quercetin, Resveratrol, Berberine, Green tea.
Where EUTECNIQ would use this
EUTECNIQ would test botanical constituents at concentrations matched to measured human exposure, include the circulating conjugates, and screen extracts for PXR, CAR and AhR-driven induction using the ICH M12 markers before any human study. None of this exists yet.
Related pages: ADME, PK and PBPK · Bioactive compounds · Bioavailability design
Health information notice
These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.
Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.
EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.